Bourgeon Capital Management’s Galmed Pharmaceuticals GLMD Stock Holding History

Bourgeon Capital Management’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-3	Closed	-$16	–	209
2023 Q4	$16	Hold	3	–	–	﹤0.01%	399
2023 Q3	$22	Hold	3	–	–	﹤0.01%	395
2023 Q2	$102	Hold	3	–	–	﹤0.01%	327
2023 Q1	$214	Hold	3	–	–	﹤0.01%	306
2022 Q4	$250	Hold	3	–	–	﹤0.01%	353
2022 Q3	$0	Hold	3	–	–	﹤0.01%	396
2022 Q2	$0	Hold	3	–	–	﹤0.01%	293
2022 Q1	$1K	Hold	3	–	–	﹤0.01%	274
2021 Q4	$1K	Hold	3	–	–	﹤0.01%	257
2021 Q3	$1K	Hold	3	–	–	﹤0.01%	268
2021 Q2	$2K	Hold	3	–	–	﹤0.01%	263
2021 Q1	$2K	Hold	3	–	–	﹤0.01%	258
2020 Q4	$2K	Hold	3	–	–	﹤0.01%	247
2020 Q3	$2K	Hold	3	–	–	﹤0.01%	254
2020 Q2	$2K	Hold	3	–	–	﹤0.01%	235
2020 Q1	$2K	Hold	3	–	–	﹤0.01%	239
2019 Q4	$3K	Hold	3	–	–	﹤0.01%	218
2019 Q3	$2K	Buy	+3	New	+$3.01K	﹤0.01%	223

Other funds holding GLMD

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

FDCDDQ

Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Allworth Financial Folsom, California $24.7B AUM 15.55% 1-Year Est. Return

Bourgeon Capital Management's GLMD Position: Q1 2024 in Review

Bourgeon Capital Management sold out of Galmed Pharmaceuticals (GLMD) in Q1 2024, closing a stake of 3 shares — an estimated $16 sold.

Bourgeon Capital Management first reported a position in GLMD in Q3 2019 and held it in 18 quarters. The position peaked at $3K in Q4 2019. 12 funds tracked by Wall St. Rank hold GLMD as of Q1 2024.

Bourgeon Capital Management reported no remaining Galmed Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Bourgeon Capital Management sold 3 Galmed Pharmaceuticals shares in Q1 2024, an estimated $16.
Bourgeon Capital Management first reported a position in Galmed Pharmaceuticals in Q3 2019 and held it in 18 quarters.
Bourgeon Capital Management's Galmed Pharmaceuticals position peaked at $3K in Q4 2019.
12 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2024.

Based on Bourgeon Capital Management's 13F filing for Q1 2024, filed 19 Apr 2024.